Intelligent Retinal Imaging Systems
IRIS is a Pensacola-based teleretinal screening platform enabling healthcare organizations to perform FDA-cleared diabetic retinopathy screenings using cloud-based, camera-agnostic software with proprietary image enhancement and remote specialist interpretation, serving 650+ providers as an affiliate of Topcon Healthcare.
- Company typePrivate
- Founded2012
- HeadquartersPensacola, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Intelligent Retinal Imaging Systems does
Intelligent Retinal Imaging Systems (IRIS) is a Pensacola, Florida-based healthcare technology company founded in 2012 that operates a cloud-based, camera-agnostic teleretinal screening platform for the early detection of diabetic retinopathy. Its core product is an FDA Class II cleared software platform (21 CFR Part 11 compliant) that integrates with Epic and other EMR systems, applies a proprietary image enhancement algorithm to fundus images, and routes cases to the IRIS Reading Center — a remote interpretation service staffed by board-certified retina specialists — for diagnosis of diabetic retinopathy, macular edema, glaucoma, and other retinal pathologies. The non-mydriatic workflow enables primary care providers and non-specialist staff to complete screenings in under 15 minutes without pupil dilation, eliminating the need for specialist referrals for the majority of cases.
IRIS generates revenue primarily through annual subscription SaaS contracts with healthcare organizations, with pricing bundled to include software licensing, image processing, remote specialist interpretation, EMR integration, and training. Hardware (tabletop or handheld fundus cameras) is sold or rented separately, and customers — primarily hospitals and health systems, FQHCs, health plans, HRA organizations, primary care practices, and labs/pharmacies — also capture downstream value through improved HEDIS/Star ratings and value-based care incentives. Go-to-market is dual-pronged: a consultative enterprise field-sales motion with a 90-day implementation timeline, and a channel partnership model in which HRA and in-home health evaluation partners (notably HealPros) deploy IRIS-trained technicians in non-clinical settings.
Following its 2025 acquisition by Topcon Healthcare, IRIS operates as an affiliate of the Topcon group from its Pensacola headquarters and is being integrated into Topcon's Harmony cloud platform and "Healthcare from the Eye" initiative, with stated expansion into diagnostic modules for cardiovascular disease, chronic kidney disease, and early Alzheimer's detection. Across more than 650 healthcare organizations, IRIS has enabled over 1.8 million screenings and identified more than 279,000 cases of diabetic retinopathy, with documented customer outcomes including screening compliance improvements from approximately 30% to over 80% at deployed health systems and quality score lifts from 30% to nearly 90%.
Intelligent Retinal Imaging Systems firmographics
Firmographics- Name
- Intelligent Retinal Imaging Systems
- Legal name
- Intelligent Retinal Imaging Systems, LLC
- Website
- https://retinalscreenings.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- IRIS is a Pensacola-based teleretinal screening platform enabling healthcare organizations to perform FDA-cleared diabetic retinopathy screenings using cloud-based, camera-agnostic software with proprietary image enhancement and remote specialist interpretation, serving 650+ providers as an affiliate of Topcon Healthcare.
- Ownership category
- akta.pro rank
Intelligent Retinal Imaging Systems industry classification
Industry- Product category
- Teleretinal Screening Software
- NAICS
- Diagnostic Imaging Centers (621512)
- SIC
- Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)
- akta.pro secondary industries
- Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB), Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI)
Keywords
Where Intelligent Retinal Imaging Systems is headquartered
LocationHeadquarters
- HQ city
- Pensacola
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Intelligent Retinal Imaging Systems business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Subscription SaaS Platform Fee: IRIS operates as a subscription-based software-as-a-service platform where healthcare organizations pay for access to the IRIS retinal screening platform, software, cloud hosting, and the IRIS Reading Center interpretation services. The subscription model includes software licensing, image processing, remote grading by board-certified specialists, and EMR integration. Implementation and training services are bundled with the subscription.
- Hardware (Fundus Camera) Sales/Rental: IRIS recommends and facilitates the procurement of fundus cameras (both tabletop and handheld) for client organizations. Camera hardware costs are separate from the software subscription, with IRIS offering camera-agnostic compatibility so clients can choose hardware that fits their budget and setting.
- Value-Based Care Financial Incentives: Healthcare organizations implementing IRIS can generate financial returns through value-based contracts, payer incentives, HEDIS/quality bonuses, and HCC/RAF adjustments by improving screening compliance rates and closing care gaps in diabetic patient populations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise subscription for healthcare organizations |
| Subscription | Annual | Payer/Health Plan and HRA organization programs |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels9 records
Intelligent Retinal Imaging Systems product offering
Product offeringCore offering
IRIS provides a cloud-based, camera-agnostic teleretinal screening platform that enables healthcare organizations to perform non-mydriatic diabetic retinopathy and other retinal pathology screenings at the point of care using compatible fundus cameras. The platform applies a proprietary image enhancement algorithm, integrates with EMR systems such as Epic, and routes images to the IRIS Reading Center, where board-certified retina specialists deliver diagnostic interpretations back into the patient's electronic health record. IRIS also facilitates fundus camera procurement and offers implementation, training, and ongoing program support to healthcare organizations.
Product overview
IRIS (Intelligent Retinal Imaging Systems) offers a unified cloud-based teleretinal screening platform designed to eliminate preventable blindness from diabetic retinopathy. The core IRIS Retinal Screening Platform integrates with various fundus cameras and EMR systems, utilizing the proprietary Image Enhancement Technology to process retinal images. The IRIS Reading Center provides remote interpretation by board-certified specialists, while the IRIS Portal delivers diagnostic results and analytics. IRIS University provides training resources, all accessible through a single integrated workflow enabling primary care providers to perform diabetic retinopathy screenings at point-of-care.
Differentiator
Problem solved
Functional benefit
Products and services
- IRIS Retinal Screening Platform Cloud-based, camera-agnostic teleretinal screening platform that enables healthcare providers to capture, enhance, and diagnose diabetic retinopathy and other retinal pathologies at the point of care; integrates with EMR systems such as Epic and is delivered as a subscription.
- IRIS Reading Center (IRC) Remote teleophthalmology diagnostic service staffed by board-certified retina specialists who review and interpret retinal images captured on the IRIS platform, returning graded reports to the client's EMR for diabetic retinopathy, macular edema, glaucoma, AMD, and cataract identification.
- IRIS University (IRIS-U) Branded eLearning/Learning Management System that delivers virtual training modules customized to the client's camera type and workflow, covering pre-implementation curriculum and ongoing training resources accessible through the IRIS Portal.
Quantifiable outcome
- Gradability rate of 92-96%, approximately 20% above industry standard where competitors average 20-30% ungradeable rates
- +5 more outcomes
Companies that use Intelligent Retinal Imaging Systems
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles5 records
Intelligent Retinal Imaging Systems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature6 records
Intelligent Retinal Imaging Systems partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Topcon HealthcareflagshipTopcon Healthcare, a global leader in digital health and ocular data solutions, acquired Intelligent Retinal Imaging Systems in 2025. The acquisition marks a major step in enhancing Topcon Healthcare's presence in primary care and reinforces connected, data-driven care. IRIS is being integrated into Topcon's Healthcare from the Eye initiative and Harmony cloud-based connected care platform. IRIS continues operating from its Pensacola headquarters as an affiliate of Topcon Healthcare. The acquisition enables bidirectional care coordination between primary care providers and eye care providers, and supports IRIS's expansion into diagnostic modules for cardiovascular disease, chronic kidney disease, and early Alzheimer's detection.
Scale indicators9 records
Recent moves5 records
Expansion highlights5 records
Intelligent Retinal Imaging Systems competitors and assessment
Company assessmentDirect peers
- Eyenuk (EyeArt AI): Eyenuk is a direct competitor offering FDA-cleared autonomous AI for diabetic retinopathy screening (EyeArt), serving primary care, health plans, and at-risk populations with a similar point-of-care screening thesis as IRIS.
- Digital Diagnostics (IDx-DR): Digital Diagnostics built IDx-DR, an FDA-authorized autonomous AI diagnostic system for diabetic retinopathy, competing head-to-head with IRIS in primary-care point-of-care DR screening programs.
- RetinaVue (by Hillrom / Baxter / Welch Allyn): RetinaVue by Hillrom/Welch Allyn offers a teleretinal screening solution combining handheld fundus cameras with reading-center and EMR integration — directly comparable to IRIS's end-to-end model used by FQHCs and health systems.
Broad incumbents
- Topcon Healthcare (parent): Topcon Healthcare is IRIS's strategic acquirer and operates a broad portfolio of ophthalmic diagnostic devices plus the Harmony cloud platform; its Healthcare from the Eye initiative now houses IRIS, making it both parent and adjacent competitor in connected ocular care.
- ZEISS Medical Technology: ZEISS is a global incumbent in ophthalmic imaging (including fundus and OCT systems) and operates across primary-care and specialty eye-care workflows; its FORUM/ZEISS Retina Workflow overlaps with the diagnostic-imaging portion of IRIS's value chain.
- Nidek: Nidek manufactures fundus cameras, OCT, and other ophthalmic diagnostic devices that integrate into DR screening programs; as a hardware incumbent, it is comparable to IRIS's camera-agnostic integration strategy on the device side.
Emerging players
- Optomed: Optomed builds handheld fundus cameras and is moving into AI-driven screening workflows for primary care, competing with one half of IRIS's stack (hardware) while partnering on the other (software/grading).
- Remidio Innovative Solutions: Remidio produces portable/AI-enabled retinal cameras and screening software for DR; IRIS has an existing commercial partnership with Remidio announced in 2017 to bring iOS-based retinal imaging into the U.S. market.
- Airdoc: Airdoc builds autonomous AI for retinal and systemic disease screening from fundus images; it competes with IRIS's reading-center and AI-enhancement capabilities in adjacent markets and is an emerging global peer in eye-as-biomarker diagnostics.
Regional players
- Aravind Eye Hospital System: Aravind operates large-scale tele-ophthalmology and DR screening programs in India using high-volume, low-cost workflows, addressing the same DR blindness-prevention mission as IRIS but in a different geographic and economic context.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Intelligent Retinal Imaging Systems social profiles
Digital presenceIntelligent Retinal Imaging Systems compliance and trust
Trust signalCompliance1 record
Intelligent Retinal Imaging Systems financial estimates
Financial estimateRevenue estimate
Valuation estimate
Intelligent Retinal Imaging Systems leadership team
Management profileNumber of profiles
Profiles3 records
Intelligent Retinal Imaging Systems funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Intelligent Retinal Imaging Systems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Intelligent Retinal Imaging Systems
What does Intelligent Retinal Imaging Systems do?
IRIS provides a cloud-based, camera-agnostic teleretinal screening platform that enables healthcare organizations to perform non-mydriatic diabetic retinopathy and other retinal pathology screenings at the point of care using compatible fundus cameras. The platform applies a proprietary image enhancement algorithm, integrates with EMR systems such as Epic, and routes images to the IRIS Reading Center, where board-certified retina specialists deliver diagnostic interpretations back into the patient's electronic health record. IRIS also facilitates fundus camera procurement and offers implementation, training, and ongoing program support to healthcare organizations.
Is Intelligent Retinal Imaging Systems a public or private company?
Intelligent Retinal Imaging Systems is a private company. It is classified as corporate owned and is currently acquired.
When was Intelligent Retinal Imaging Systems founded?
Intelligent Retinal Imaging Systems was founded in 2012. It employs 11 to 50 people.
Where is Intelligent Retinal Imaging Systems based?
Intelligent Retinal Imaging Systems is headquartered in Pensacola, United States, in the North America region.
How does Intelligent Retinal Imaging Systems make money?
Three revenue lines are on record. Subscription SaaS Platform Fee is the primary driver. The others are hardware (Fundus Camera) Sales/Rental and value-Based Care Financial Incentives.
Who are Intelligent Retinal Imaging Systems's main competitors?
Direct peers on record are Eyenuk (EyeArt AI), Digital Diagnostics (IDx-DR) and RetinaVue (by Hillrom / Baxter / Welch Allyn). Broad incumbents are Topcon Healthcare (parent), ZEISS Medical Technology and Nidek. Emerging players are Optomed, Remidio Innovative Solutions and Airdoc. Aravind Eye Hospital System is listed as a regional player.
Does Intelligent Retinal Imaging Systems have an API?
No public API is recorded for Intelligent Retinal Imaging Systems.
What industry is Intelligent Retinal Imaging Systems in?
Intelligent Retinal Imaging Systems's product category is Teleretinal Screening Software. Its primary akta.pro industry code is HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers, with a secondary code of HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography). Its NAICS code is 621512 and its SIC code is 3827.